<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00089128</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000378047</org_study_id>
    <secondary_id>MUSC-100615</secondary_id>
    <secondary_id>PHARMACIA-440EONCO020298</secondary_id>
    <secondary_id>MUSC-HR-10212</secondary_id>
    <nct_id>NCT00089128</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer</brief_title>
  <official_title>Phase II Study Of Gemcitabine And CPT-11 (Irinotecan) In Locally Advanced Or Metastatic Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different&#xD;
      ways to stop tumor cells from dividing so they stop growing or die. Combining more than one&#xD;
      drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving gemcitabine together with irinotecan&#xD;
      works in treating patients with locally advanced or metastatic bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine response in patients with locally advanced or metastatic transitional cell&#xD;
           carcinoma of the bladder treated with gemcitabine and irinotecan.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the duration of response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the tolerance to and toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the median and progression-free survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE: Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on&#xD;
      days 1 and 8. Courses repeat every 21 days in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients with responding disease receive 2 additional courses beyond&#xD;
      best response.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual&#xD;
  </why_stopped>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Proportion</measure>
    <time_frame>From registration until time of complete response or partial response</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>From registration until disease progression among patients who had at least a partial response.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events as Assessed by NCI CTC Version 2.0</measure>
    <time_frame>From the day of first dose until the end of study, an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Time between registration and disease progression or death, whichever comes first.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine and Irnotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <arm_group_label>Gemcitabine and Irnotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <arm_group_label>Gemcitabine and Irnotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed transitional cell carcinoma of the bladder&#xD;
&#xD;
               -  Locally advanced or metastatic disease&#xD;
&#xD;
          -  Unidimensionally measurable disease by physical exam or imaging study&#xD;
&#xD;
               -  The following are not considered measurable disease:&#xD;
&#xD;
                    -  Bone only disease&#xD;
&#xD;
                    -  Pleural or peritoneal effusions&#xD;
&#xD;
                    -  CNS lesions&#xD;
&#xD;
                    -  Irradiated lesions unless disease progression was documented after&#xD;
                       radiotherapy&#xD;
&#xD;
          -  Not amenable to surgery&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No active inflammatory bowel disease&#xD;
&#xD;
          -  No significant bowel obstruction&#xD;
&#xD;
          -  No chronic diarrhea&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other active malignancy except nonmelanoma skin cancer&#xD;
&#xD;
          -  No mental incapacitation or psychiatric illness that would preclude giving informed&#xD;
             consent&#xD;
&#xD;
          -  No other severe disease that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No more than 1 prior platinum-based chemotherapy regimen&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No prior irinotecan or gemcitabine&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent hormones except steroids for adrenal failure, hormones for&#xD;
             non-disease-related conditions (e.g., insulin for diabetes), and intermittent&#xD;
             dexamethasone as an antiemetic&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent palliative radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent participation in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uzair B. Chaudhary, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gustavo Leone</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina, Hollings Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hollings Cancer Center at Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>August 4, 2004</study_first_submitted>
  <study_first_submitted_qc>August 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2004</study_first_posted>
  <results_first_submitted>May 4, 2018</results_first_submitted>
  <results_first_submitted_qc>June 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2018</results_first_posted>
  <last_update_submitted>June 13, 2018</last_update_submitted>
  <last_update_submitted_qc>June 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <keyword>recurrent bladder cancer</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gemcitabine and Irnotecan</title>
          <description>On day 1 and day 8 of each 21 day cycle:&#xD;
gemcitabine hydrochloride 1,000 mg/m2 IV over 30 minutes&#xD;
irinotecan hydrochloride 100mg/m2 IV over 90 minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gemcitabine and Irnotecan</title>
          <description>On day 1 and day 8 of each 21 day cycle:&#xD;
gemcitabine hydrochloride 1,000 mg/m2 IV over 30 minutes&#xD;
irinotecan hydrochloride 100mg/m2 IV over 90 minutes</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Proportion</title>
        <time_frame>From registration until time of complete response or partial response</time_frame>
        <population>Data for this endpoint was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine and Irnotecan</title>
            <description>On day 1 and day 8 of each 21 day cycle:&#xD;
gemcitabine hydrochloride 1,000 mg/m2 IV over 30 minutes&#xD;
irinotecan hydrochloride 100mg/m2 IV over 90 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Response Proportion</title>
          <population>Data for this endpoint was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <time_frame>From registration until disease progression among patients who had at least a partial response.</time_frame>
        <population>Data for this endpoint was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine and Irnotecan</title>
            <description>On day 1 and day 8 of each 21 day cycle:&#xD;
gemcitabine hydrochloride 1,000 mg/m2 IV over 30 minutes&#xD;
irinotecan hydrochloride 100mg/m2 IV over 90 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <population>Data for this endpoint was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Adverse Events as Assessed by NCI CTC Version 2.0</title>
        <time_frame>From the day of first dose until the end of study, an average of 6 months</time_frame>
        <population>data for this endpoint was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine and Irnotecan</title>
            <description>On day 1 and day 8 of each 21 day cycle:&#xD;
gemcitabine hydrochloride 1,000 mg/m2 IV over 30 minutes&#xD;
irinotecan hydrochloride 100mg/m2 IV over 90 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Adverse Events as Assessed by NCI CTC Version 2.0</title>
          <population>data for this endpoint was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <time_frame>Time between registration and disease progression or death, whichever comes first.</time_frame>
        <population>data for this endpoint was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine and Irnotecan</title>
            <description>On day 1 and day 8 of each 21 day cycle:&#xD;
gemcitabine hydrochloride 1,000 mg/m2 IV over 30 minutes&#xD;
irinotecan hydrochloride 100mg/m2 IV over 90 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <population>data for this endpoint was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from start of treatment until end of study, an average of 6 months</time_frame>
      <desc>The data for this endpoint was not collected</desc>
      <group_list>
        <group group_id="E1">
          <title>Gemcitabine and Irnotecan</title>
          <description>On day 1 and day 8 of each 21 day cycle:&#xD;
gemcitabine hydrochloride 1,000 mg/m2 IV over 30 minutes&#xD;
irinotecan hydrochloride 100mg/m2 IV over 90 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kate Anderton</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-2708</phone>
      <email>anderton@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

